ANTIBODY ANALYTICS LIMITED - Profile & Financials

Accounts Submitted 8 Sept 2025

Confirmation Statement Submitted 3 Dec 2025

Net assets £1.19M £427.14K 2023 year on year

Total assets £9.44M £5.96M 2023 year on year

Total Liabilities £8.24M £5.53M 2023 year on year

Charges 4

4 outstanding

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

Rouken Discovery Centre Braidhurst Industrial Estate Motherwell North Lanarkshire ML1 3ST Scotland

Telephone

0016 985 34450

ahannigan@antibodyanalytics.com

Website

antibodyanalytics.com

Credit Report

Discover ANTIBODY ANALYTICS LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2023

Type Total Exemption Full

Next accounts 31 December 2024

Due by 30 September 2025 9 months

Net Assets, Total Assets & Total Liabilities (2016–2023)

Cash in Bank

£6.27M

Increased by £5.36M (+587%)

Net Assets

£1.19M

Increased by £427.14k (+56%)

Total Liabilities

£8.24M

Increased by £5.53M (+203%)

Turnover

N/A

Employees

Increased by 20 (+31%)

Debt Ratio

87%

Increased by 9 (+12%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2023 Dec Year End	2022 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

£398k awarded

Show:

Investors (0)

No investor information available

Share Capital

Share allotments and capital structure

4 Allotments 2,218 Shares £142k Total

Date From	Share Class	Shares Allotted	Amount Raised	Price/Share
12 Oct 2023	C ORDINARY	1,101	£142k	£128.82
13 Mar 2019	ORDINARY B	48	£0.48	£0.01
13 Mar 2019	ORDINARY A	970	£9.7	£0.01
24 Nov 2015	ORD	99	£99	£1

Officers

3 active 4 resigned

Show resigned officers

						Status
Alan Thomas Mcdonald	Director	British	Scotland	46	3 May 2024	Active
Andrew Richard Upsall	Director	British	Scotland	46	11 Jan 2016	Active
Michahaila Julia Downie	Director	British	Scotland	47	24 Nov 2015	Active

Shareholders

Shareholders (9)


Project Steel Acquireco Limited	90.1%	10,000	Ordinary	4 Dec 2023
Project Steel Acquireco Limited	9.9%	1,101	C Ordinary	4 Dec 2023
Michahaila Julia Downie	0.0%	0	Ordinary	4 Dec 2023

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Project Steel Acquireco Limited

United Kingdom

Active

Notified 12 Oct 2023

Nature of Control

Ownership Of Shares 75 To 100 Percent
Voting Rights 75 To 100 Percent
Right To Appoint And Remove Directors

Andrew Richard Upsall

Ceased 12 Oct 2023

Ceased

Michahaila Julia Downie

Ceased 12 Oct 2023

Ceased

See All Controllers

Group Structure

PROJECT STEEL ACQUIRECO LIMITED united kingdom voting rights 25 to 50 percent

NORTHEDGE CAPITAL NOMINEE LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent

NORTHEDGE CAPITAL LLP united kingdom

ANTIBODY ANALYTICS LIMITED Current Company

ROUKEN BIO LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors

Charges

4 outstanding

Documents

Company Filings

Date	Category	Description	Document
3 Dec 2025	Confirmation Statement	Confirmation statement made on 2025-11-26 with updates	View(4 pages)
8 Sept 2025	Accounts	Annual accounts made up to 2024-12-31	View(30 pages)
4 Dec 2024	Confirmation Statement	Confirmation statement made on 2024-11-26 with updates	View(4 pages)
26 Sept 2024	Officers	Change to director Mr Alan Thomas Mcdonald on 2024-09-26	View(2 pages)
26 Sept 2024	Persons With Significant Control	Change to Project Steel Acquireco Limited as a person with significant control on 2024-09-26	View(2 pages)